BOTH (Bioethics) Short-Term Debt: $0.59 Mil (As of Dec. 2024)


What is Bioethics Short-Term Debt?

Bioethics BOTH Short-Term Debt is $0.59 Mil as of Dec. 2024.

Bioethics's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.59 Mil.

Bioethics's quarterly Short-Term Debt increased from Jun. 2024 ($0.49 Mil) to Sep. 2024 ($0.50 Mil) and increased from Sep. 2024 ($0.50 Mil) to Dec. 2024 ($0.59 Mil).

Bioethics's annual Short-Term Debt increased from Dec. 2022 ($0.42 Mil) to Dec. 2023 ($0.44 Mil) and increased from Dec. 2023 ($0.44 Mil) to Dec. 2024 ($0.59 Mil).

Bioethics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bioethics Short-Term Debt Related Terms

Bioethics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Bioethics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioethics Short-Term Debt Chart

Bioethics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.40 0.42 0.44 0.59

Bioethics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.45 0.49 0.50 0.59
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.59 Mil mean?
Bioethics (BOTH) has a Short-Term Debt of $0.59 Mil as of Dec. 2024.
Is Bioethics' Short-Term Debt too high?
Bioethics' current Short-Term Debt is $0.59 Mil.
How does Bioethics' Short-Term Debt compare to NXTFF and BISA?
Bioethics' Short-Term Debt of $0.59 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Diversified Financial Services company?
A good Short-Term Debt depends on the Diversified Financial Services industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Bioethics's current Short-Term Debt is $0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioethics stock overvalued right now?
Bioethics (BOTH) has a current Short-Term Debt of $0.59 Mil. The current Short-Term Debt is $0.59 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Bioethics (BOTH), the current Short-Term Debt is $0.59 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioethics Business Description

Address 1661 Lakeview Circle, Ogden, UT, USA, 84403
Bioethics Ltd is a shell company that conducts no active business operations and is seeking business opportunities for acquisition or participation by the company.